EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier?

Valerio Gristina, Pasquale Pisapia iD, Nadia Barraco, Francesco Pepe, Federica Iacono, Maria La Mantia, Marta Peri, Antonio Galvano, Lorena Incorvaia, Giuseppe Badalamenti, Viviana Bazan, Giancarlo Troncone und 2 weitere

Expert Review of Molecular Diagnostics · 2023

DOI: 10.1080/14737159.2023.2245752 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Molecular Diagnostics, 2023. Verfasst von Valerio Gristina und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 80 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: To date, several emerging biomarkers have gained considerable interest in the field of predictive molecular oncology. The advent of precision medicine has led to the development of innovative drugs targeting rare molecular pathways independently from histology, defined as tissue-agnostic drugs. AREAS COVERED: Although there is a lot of promise for this new tissue-agnostic model in the oncological scenario, crucial issues from both the diagnostic and therapeutic standpoint are emerging. This review aims to critically examine the role of tissue-agnostic biomarkers in different solid tumors, focusing on the prevalence and methods of detection of agnostic biomarkers together with drug approvals to guide clinicians in this evolving landscape. EXPERT OPINION: To strengthen the framework for tissue-agnostic approvals, the dialogue between regulatory, industrial, and academic parties should be intensified. Critical questions include the development of an efficient network system that can overcome the heterogeneity of patients' inclusion criteria along with the increasingly difficult interpretation of next-generation sequencing (NGS) profiling technologies. Cost-effectiveness and risk-benefit studies are needed in the national context considering the modalities of access to diagnostic tests and reimbursement of treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorNeoplasmsHumansPrecision MedicineHigh-Throughput Nucleotide SequencingMolecular Diagnostic Techniques

Stichwörter der Autor:innen

MTBNGSbiomarkerspredictivetissue-agnostic

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.
  • Department of Public Health, University Federico II of Naples, Naples, Italy.
  • Department of Experimental Biomedicine and Clinical Neurosciences, University of Palermo, Palermo, Italy.

ORCID-Profile: Pasquale Pisapia

Zitieren

APA

Gristina, V., Pisapia, P., Barraco, N., Pepe, F., Iacono, F., La Mantia, M., Peri, M., Galvano, A., Incorvaia, L., Badalamenti, G., Bazan, V., Troncone, G., Russo, A., & Malapelle, U. (2023). The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier?. Expert Review of Molecular Diagnostics. https://doi.org/10.1080/14737159.2023.2245752

Vancouver

Gristina V, Pisapia P, Barraco N, Pepe F, Iacono F, La Mantia M, et al. The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier?. Expert Review of Molecular Diagnostics. 2023. doi:10.1080/14737159.2023.2245752

BibTeX
@article{Gristina2023,
  author = {Gristina, Valerio and Pisapia, Pasquale and Barraco, Nadia and Pepe, Francesco and Iacono, Federica and La Mantia, Maria and Peri, Marta and Galvano, Antonio and Incorvaia, Lorena and Badalamenti, Giuseppe and Bazan, Viviana and Troncone, Giancarlo and Russo, Antonio and Malapelle, Umberto},
  title = {The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier?},
  journal = {Expert Review of Molecular Diagnostics},
  year = {2023},
  doi = {10.1080/14737159.2023.2245752}
}
Kostenlos starten →